Work

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer

Year: 2019

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2019.05.003

Authors: Joyce F. Liu, Kathryn P. Gray, Alexi A. Wright, Susana Campos, Panagiotis A. Konstantinopoulos, Ariana Peralta, Kimberley MacNeill, Stephanie Morrissey, Christin Whalen, Deborah Dillon, Ursula A. Matulonis

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Brigham and Women's Hospital

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Comprehensive Cancer Network

OpenAlex ID: W2945175225

FWCI: 1.654

Cites: 32

Cited by: 46

Related to: 10